Moxifloxacin Ophthalmic Solution USP 0.5%, 3 mL, Packaged and Distributed By: Direct Rx Dawsonvil...
FDA Drug Recall #D-0637-2022 — Class II — February 17, 2022
Recall Summary
| Recall Number | D-0637-2022 |
| Classification | Class II — Moderate risk |
| Date Initiated | February 17, 2022 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Direct Rx |
| Location | Dawsonville, GA |
| Product Type | Drugs |
| Quantity | 44 bottles |
Product Description
Moxifloxacin Ophthalmic Solution USP 0.5%, 3 mL, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 Dist. By Aurobindo Pharma USA, Inc. East Windsor, NJ 08520, NDC 72189-076-05
Reason for Recall
Failed impurities/degradation specifications
Distribution Pattern
Florida
Lot / Code Information
Lot#: 18JA2218 Exp. 6/30/23; 20DE2104 Exp. 6/30/23; 08NO2111 Exp. 6/30/23
Other Recalls from Direct Rx
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0567-2025 | Class II | Duloxetine D/R, 20 mg, 30 Caps, 30-count bottle... | Mar 7, 2025 |
| D-0568-2025 | Class II | Duloxetine D/R, 30 mg, 30 Caps, RX Only, Packag... | Mar 7, 2025 |
| D-0364-2025 | Class II | CIPROFLOXACIN OPHTH SOLUTION, 0.3% 5mL bottle, ... | Jan 31, 2025 |
| D-0041-2025 | Class II | Ibuprofen 800mg, Generic for: Motrin, Each tabl... | Aug 9, 2024 |
| D-0508-2023 | Class II | Alprazolam C-IV, 1 mg, packaged in a) 30 Tabs p... | Mar 22, 2023 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.